ImmuPharma (LON:IMM) Trading Up 27.3% - Should You Buy?

Key Points

• ImmuPharma's shares surged by 27.3%, reaching a trading price of GBX 12.60 ($0.17), although trading volume fell 46% from average levels.
• The company has a market capitalization of £63.34 million and reported a net margin of 3,519.56% with an earnings per share forecast of -339.0000022 for the current fiscal year.
• ImmuPharma focuses on peptide-based therapeutics for autoimmune diseases, with its lead program, Lupuzor™, targeting the treatment of Lupus.

ImmuPharma plc (LON:IMM - Get Free Report) shares were up 27.3% on Saturday . The stock traded as high as GBX 12.75 ($0.17) and last traded at GBX 12.60 ($0.17). Approximately 4,543,810 shares were traded during trading, a decline of 46% from the average daily volume of 8,432,391 shares. The stock had previously closed at GBX 9.90 ($0.13).

ImmuPharma Trading Up 27.3%

The company has a market capitalization of £63.34 million, a P/E ratio of -1,415.73 and a beta of 1.53. The firm's 50 day moving average price is GBX 7.92 and its two-hundred day moving average price is GBX 4.36.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. Analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.